Moore Capital Management »

Revance Therapeutics shares owned by Moore Capital Management

Quarter-by-quarter ownership of Revance Therapeutics (RVNC) shares owned by Moore Capital Management from 13F filings

Historical chart of Moore Capital Management investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by Moore Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by Moore Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.3M 150k 8.79
2023-09-30 $1.8M 160k 11.47
2023-06-30 $1.4M 55k 25.31
2014-06-30 $3.4M 100k 34.00

More positions owned by Moore Capital Management

Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Meta Platforms Cl A (META)
Amazon (AMZN)
Ishares Tr Msci Emg Mkt Etf (EEM)
Spdr Ser Tr S&p Biotech (XBI)
Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Palo Alto Networks Note 0.375% 6/0 (Principal)
Ally Financial (ALLY)
Allstate Corporation (ALL)
Spdr Ser Tr S&p Regl Bkg (KRE)
Vaneck Etf Trust Gold Miners Etf (GDX)
salesforce (CRM)
Progressive Corporation (PGR)
Vertiv Holdings Com Cl A (VRT)
Select Sector Spdr Tr Indl Call Option (XLI)

View all positions for Moore Capital Management

Top funds holding Revance Therapeutics

Palo Alto Investors
Vanguard Group
Franklin Resources
Jpmorgan Chase & Co
Jennison Associates
Bamco
Walleye Trading Advisors
Goldman Sachs Group
Rice Hall James & Associates
Charles Schwab Investment Management
Citadel Advisors
Wellington Management Company
D. E. Shaw & Co
HighTower Advisors
Balyasny Asset Management

View all funds holding Revance Therapeutics